Risk identification, risk assessment, and risk management of abusable drug formulations

Drug and Alcohol Dependence

Volumn 83, Issue SUPPL. 1, 2006, Pages

  Wright IV, Curtis ^a   Kramer, E Douglas ^a   Zalman, Mary Ann ^a   Smith, Meredith Y ^a   Haddox, J David ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

Abuse potential; Medical use; Prescription drug abuse; Regulation

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BUPRENORPHINE; CODEINE; CYCLOOXYGENASE 1 INHIBITOR; FENTANYL; FENTANYL CITRATE; HYDROCODONE; METHADONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE;

ALCOHOL CONSUMPTION; ANALGESIA; ARTICLE; CLINICAL PHARMACOLOGY; DOSE CALCULATION; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG APPROVAL; DRUG CONTAMINATION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PAIN; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION;

CHEMISTRY, PHARMACEUTICAL; HUMANS; NARCOTICS; OVERDOSE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RISK MANAGEMENT; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 33646029117     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2005.12.012     Document Type: Article

References (54)

1. Auriacombe M., Franques P., and Tigno I.J. Deaths attributable to methadone vs buprenorphine in France. J. Am. Med. Assoc. 285 (2001) 45
2. Baum C., Hsu J.P., and Nelson R.C. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep. 102 (1987) 426-429
3. Brookoff D. Abuse potential of various opioid medications. J. Gen. Intern. Med. 8 (1993) 688-690
4. ® (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 57 (1999) 7-22
5. Cone E.J., Fant R.V., Rohay J.M., Caplan Y.H., Ballina M., Reder R.F., and Haddox J.D. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J. Anal. Toxicol. 28 (2004) 217-225
6. Dasgupta, N., 2003. Analgesic for a Rural Legend: OxyContin Abuse in Maine. Masters Thesis. Yale School of Medicine, Department of Epidemiology, New Haven, CT.
7. Dasgupta, N., Kramer, E.D., Zalman, M.-A., Carino, S., Smith, M.Y., Haddox, J.D., Wright IV, C., in press. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend.
8. De Wit H., Bodker B., and Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 107 (1992) 352-358
9. Friedmann N., de Kater A.W., Butera P.G., Webster L.R., Ratcliff S., van Raders P.A., and Langford R.M. Remoxy™, a novel drug candidate, deters oxycodone abuse in humans. Barcelona Pain Conference. Barcelona, Spain (2004) (abstract)
10. In: Gail M.H., and Benichou J. (Eds). Encyclopedia of Epidemiologic Methods (2000), John Wiley & Sons Ltd., New York
11. Gilson A.M., Ryan K.M., Joranson D.E., and Dahl J.L. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J. Pain Symptom. Manage 28 (2004) 176-188
12. Griffiths R.R., McLeod D.R., Bigelow G.E., Liebson I.A., Roache J.D., and Nowowieski P.A. Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J. Pharmacol. Exp. Ther. 229 (1984) 501-508
13. Hammersley R., Cassidy M.T., and Oliver J. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990-October 1992. Addiction 90 (1995) 959-965
14. Harwood H., Fountain D., and Livermore G. The Economic Costs of Alcohol and Drug Abuse in the United States-1992 (1998), National Institute on Drug Abuse, Rockville, MD (publication No 98-4327)
15. Hoffman R.S., Wipfler M.G., Maddaloni M.A., and Weisman R.S. Has the New York State triplicate benzodiazepine prescription regulation influenced sedative-hypnotic overdoses?. NY State J. Med. 91 (1991) 436-439
16. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35 (1978) 501-516
17. Javaid J.I., Fischman M.W., Schuster C.R., Dekirmenjian H., and Davis J.M. Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science 202 (1978) 227-228
18. Jenkins P. Synthetic panics. The symbolic politics of designer drugs (1999), New York University Press, New York/London
19. Joranson D.E., Ryan K.M., Gilson A.M., and Dahl J.L. Trends in medical use and abuse of opioid analgesics. J. Am. Med. Assoc. 283 (2000) 1710-1714
20. de Kater A.W., Friedmann N., Butera P.G., Ratcliff S., van Raders P.A., Langford R.M., and Schoenhard G.L. Clinical pharmacokinetics of oxycodone after single and multiple doses of Remoxy™; a novel, abuse-resistant long-acting oxycodone formulation. Barcelona Pain Conference. Barcelona, Spain (2004) (abstract)
21. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 121 (2001) 65-69
22. Marsch L.A., Bickel W.K., Badger G.J., Rathmell J.P., Swedberg M.D.B., Jonzon B., and Norsten-Hoog C. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J. Pharmacol. Exp. Ther. 299 (2001) 1056-1065
23. Ministry of the Interior. Drug use and drug trafficking in France: 1998 Annual Statistics (1999), Director's Office of the National Police, Central Directorate of the Judicial Police, Central Office Against Illicit Drug Trafficking, Paris, France pp. 1-106 (in French)
24. Mumford G.K., Evans S.M., Fleishaker J.C., and Griffiths R.R. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57 (1995) 356-365
25. Musto D.F. Drugs in America. A Documentary History (2002), New York University Press, New York/London
26. Novak S., Nemeth W.C., and Lawson K.A. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med. 5 (2004) 59-65
27. Office of National Drug Control Policy. The Economic Costs of Drug Abuse in the United States, 1992-1998 (2001), Executive Office of the President, Washington, DC (publication no. NCJ-190636)
28. Reed D.A., and Schnoll S.H. Abuse of a pentazocine-naloxone combination. J. Am. Med. Assoc. 256 (1986) 2562-2564
29. Reynaud M., Petit G., Potard D., and Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93 (1998) 1385-1392
30. Rice, D.P., Kelman, S., Miller, L.S., Dunmeyer, S., 1985. The Economic Costs of Alcohol and Drug Abuse and Mental Illness: 1985. Report Submitted to the Alcohol, Drug Abuse, and Mental Health Administration. U.S. Department of Human Services. DHHS Publication No. (ADM) 90-1694. Institute for Health and Aging, University of California, San Francisco, CA.
31. Riegelman R.K., and Hirsch R.P. Studying a study and testing a test: How to read the health science literature. 3rd ed. (1996), Little, Brown Company, New York pp. 213-218
32. Sellers E.M., Chilcoat H.D., Gorodetzky C.W., Reidenberg M.M., Strain E.C., Woods J.H., Zacny J.P., Henningfield J.E., and Johanson C.-E. Abuse liability assessment of CNS drugs: conclusions, recommendations and research priorities. Drug Alcohol Depen. 70 Suppl. 3 (2003) S107-S114
33. Slovic P., Fischoff B., and Lichtenstein S. Facts and fears: understanding perceived risk. In: Schwing R.C., and Albers Jr. W.A. (Eds). Societal Risk Assessment, How Safe is Safe Enough? (1980), Plenum Press, New York 181-216
34. Strain E.C., Preston K.L., Liebson I.A., and Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261 (1992) 985-993
35. Strain E.C., Preston K.L., Liebson I.A., and Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J. Pharmacol. Exp. Ther. 272 (1995) 628-638
36. Substance Abuse and Mental Health Services Administration, 2002a. Office of Applied Studies, Results from the 2001 National Household Survey on Drug Abuse: Volume II. Technical Appendices and Selected Data Tables. NHSDA series H-18. DHHS Publication No. (SMA) 02-3759, Rockville, MD.
37. Substance Abuse and Mental Health Services Administration, 2002b. Office of Applied Studies, Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1994-2001. DAWN Series D-21, DHHS Publication No. (SMA) 02-3635, Rockville, MD.
38. Substance Abuse and Mental Health Services Administration, 2002c. Office of Applied Studies, Methodology. Series M-4, DHHS Publication No. (SMA) 02-3754, Rockville, MD (accessed January 8, 2005) http://dawninfo.samhsa.gov/files/report.pdf.
39. Substance Abuse and Mental Health Services Administration, 2003a. Office of Applied Studies, Overview of Findings from the 2003 National Survey on Drug Use and Health National Findings. Office of Applied Studies, NSDUH Series H-24. DHHS Publication No. (SMA) 04-3963, Rockville, MD (accessed May 5, 2005) http://oas.samhsa.gov/nhsda.htm-NHSDAinfo.
40. Substance Abuse and Mental Health Services Administration, 2003b. Office of Applied Studies, Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002. DAWN Series D-24. DHHS Publication No. (SMA) 03-3780, Rockville, MD.
41. Substance Abuse and Mental Health Services Administration, 2004. Office of Applied Studies, Results from the 2003 National Household Survey on Drug Abuse: National Findings Office of Applied Studies, NSDUH Series H-25. DHHS Publication No. (SMA) 04-3964, Rockville, MD.
42. Sunshine A., Axtmayer R., Olson N.Z., Laska E., and Ramos I. Analgesic efficacy of pentazocine versus a pentazocine-naloxone combination following oral administration. Clin. J. Pain 4 (1988) 35-40
43. Tracqui A., Kintz P., and Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 22 (1998) 430-434
44. Tracqui A., Tournoud C., Flesch F., Kopferschmitt J., Kintz P., Deveaux M., Ghysel M.H., Marquet P., Pepin G., Petit G., Jaeger A., and Ludes B. Acute poisoning during substitution therapy based on high-dosage buprenorphine. Tewnty-nine clinical cases-20 fatal cases]. Presse Med. 28 (1998) 557-561 (in French)
45. United Nations Office for Drug Control and Crime Prevention. Global Illicit Drug Trends (1999), United Nations, New York. http://www.unodc.org/pdf/report_1999-06-01_1.pdf (accessed May 31, 2005)
46. United Nations Office on Drugs and Crime (UNODC). Global Illicit Drug Trends (2003), United Nations, New York. http://www.unodc.org/pdf/trends2003_www_E.pdf (accessed May 31, 2005)
47. U.S. Department of Health and Human Services. Guidance for Industry, 2005. Development and Use of Risk Minimization Action Plans (2005), Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. http://www.fda.gov/cber/guidelines.htm (accessed May 5, 2005)
48. U.S. Department of Health and Human Services. Guidance for Industry, 2005. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (2005), Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. http://www.fda.gov/cber/guidelines.htm (accessed May 5, 2005)
49. U.S. General Accounting Office Report, 2003. GAO-04-110 Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem (accessed May 25, 2005) http://www.gao.gov/htext/d04110.html.
50. Volkow N.D., and Swanson J.M. Variables that affect the clinical use and abuse of methylphenidate. Am. J. Psychiatry 160 (2003) 1909-1918
51. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55 (1994) 569-580
52. Walsh S.L., Preston K.L., Bigelow G.E., and Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274 (1995) 361-372
53. Weintraub M., Singh S., Byrne L., Maharaj K., and Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. J. Am. Med. Assoc. 266 (1991) 2392-2397
54. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 69 (2003) 215-232